Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

FDA approves Xeris’ glucagon pen for low blood sugar

The U.S. Food and Drug Administration approved Xeris Pharmaceuticals Inc.’s glucagon pen Gvoke, which aims to treat severely low sugar levels in diabetes patients.

Read More »

AstraZeneca diabetes drug shows heart failure promise

AstraZeneca made strides toward the company’s goal of adding heart failure to the conditions that can be treated by Farxiga, putting the diabetes drug ahead of a rival medicine from Eli Lilly.

Read More »

FDA Approves First Needle-Free Glucagon to Treat Severe Hypoglycemia

The FDA approved Eli Lilly’s Baqsimi (glucagon) nasal powder 3 mg to treat severe hypoglycemia in diabetics 4 years of age and older.

Read More »

AstraZeneca’s Farxiga fails to receive U.S. approval for type 1 diabetes

The U.S. Food and Drug Administration declined to approve AstraZeneca Plc’s diabetes treatment Farxiga for use as a supplement to insulin in adults with a rare type of the condition.

Read More »

Most older adults with ‘prediabetes’ don’t develop diabetes

Older adults with slightly elevated blood sugar – sometimes called “prediabetes” – usually do not develop full-blown diabetes, a Swedish study suggests.

Read More »

Sanofi’s Soliqua Edges Out Competitors in Blood Sugar Control Trial

Sanofi presented data from the company’s Phase III LixiLan-G trial demonstrating that Soliqua/Suliqua showed superior decrease of average blood sugar level (HbA1c) after 26 weeks compared to other GLP-1 receptor agonists.

Read More »

Abbott device helps in cutting blood sugar in type 2 diabetics: study

Insulin-dependent patients with T2D saw a significant drop in blood sugar levels after wearing Abbott’s continuous glucose monitoring system compared with those who use routine fingerstick testing.

Read More »

Zealand Pharma’s Severe Hypoglycemia Treatment Hits the Mark in Another Phase III Trial

Shares of Zealand Pharma A/S were up more than 2 percent after the company announced that dasiglucagon, a potential treatment for severe hypoglycemia, hit the mark in a Phase III study.

Read More »

Novo Nordisk Q1 2019 profit tops forecast

Danish drugmaker Novo Nordisk beat first-quarter 2019 operating profit forecasts, helped by higher sales of the company’s biggest new drug hope, a treatment for type 2 diabetes.

Read More »

Morning exercise, short breaks from sitting lower high blood pressure

Combining 30 minutes of morning exercise with short walking breaks throughout the day may help control blood pressure.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom